Mahasweta Gooptu
@MGooptu
Followers
147
Following
350
Media
4
Statuses
113
Adult BMT Faculty at Dana-Farber Cancer Institute Assistant Professor of Medicine, Harvard Medical School Interests: Allogeneic transplantation
Boston
Joined February 2020
Donor selection guidelines are out! Grateful to have worked with amazing colleagues and the @CIBMTR and @nmdp_org on this effort. Advances in GVHD prophylaxis support moving beyond strict HLA models toward an integrated approach that brings us closer to a suitable donor for every
Just Published in @ASTCT_Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more:
3
5
28
1
25
105
India’s first indigenous CAR-T therapy is now peer-reviewed in @TheLancetHaem , showing a 73% response rate—marking a breakthrough in accessible, cutting-edge cancer treatment.
2
12
43
Congratulations to @DanaFarber researcher Joseph H. Antin, MD, who received the @ASTCT Lifetime Achievement Award during #Tandem25. He was honored for his ongoing contributions to cellular therapy by advancing scientific knowledge in the field.
1
6
19
Congratulations to Joseph Antin, MD, recipient of the @ASTCT Lifetime Achievement Award. This recognition is given to a physician who has made continuing contributions to the BMT and cellular therapy fields through the advancement of knowledge through basic or clinical science.
1
6
43
Contributions that cannot be quantified..one of the true pioneering giants in transplantation !! Congratulations Joe Antin :). @DrCCutler @DanaFarberNews
Congratulations, Dr. Antin as @ASTCT Lifetime Achievement Award! Well deserved! 2025 @ASTCT @CIBMTR Tandem Meetings #Tandem25
0
1
11
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia https://t.co/xocBgIL3Rm by Dr. Luskin et al. #leusm #ALL 100% CR. At day 84, 100% of patients achieved complete cytogenetic remission. At day 84, 74% and 26% achieved BCR::ABL1
1
34
135
Excited to share our new manuscript co-authored by @DanaFarber BMT mentors Dr. Gooptu (@MGooptu) and Dr. Soiffer: How I Treat AML relapse after allogeneic HCT: https://t.co/I4TliFtnhZ No one-size fits all approach to this challenging situation, learned a ton writing it!
1
1
8
Great experience collaborating with Moses for this review!! Star mentees make our jobs easy :) @haematognomist
Excited to share our new manuscript co-authored by @DanaFarber BMT mentors Dr. Gooptu (@MGooptu) and Dr. Soiffer: How I Treat AML relapse after allogeneic HCT: https://t.co/I4TliFtnhZ No one-size fits all approach to this challenging situation, learned a ton writing it!
0
2
7
🚨 New findings from the @BMTCTN 1703 trial: Post-transplant cyclophosphamide (PTCy) lowers patient-reported #GVHD symptom burden vs Tac/MTX in the first year after transplant. 📊🩺 #PTCyRules Congrats, team!! 💪 @GvHD_Meade @MediHumdani
https://t.co/ESYwSDrgkM
ascopubs.org
The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF)...
2
16
41
An instant classic!! Executed by some of the smartest people I know :D @sghmd @GvHD_Meade @MediHumdani @DrMiguelPerales @BrianShafferMD
Two years ago @sghmd presented #BMTCTN1703 at the @ASH_hematology meeting! That was a good day! #PTCyRules @MediHumdani @MGooptu @BrianShafferMD @DrMiguelPerales @AndrewRezvani
0
1
6
Amazing to have been part of this endeavour! #donorsforeveryone
@DrStevenDevine @BrianShafferMD @amjimenezmd @DrMonzrAlMalki @JeffAuletta @spellman_s
.@MGooptu, @DanaFarber, and collaborators confirm a new approach to stem cell transplant donor matching that that expands access to safe hematopoietic stem cell transplants across all racial and ethnic backgrounds. https://t.co/vy8dHF0boT
0
5
14
🚨Breaking News/Good News from #ASH24🚨 >90% 1-year OS in PTCy-treated alloHCT recipients age 70+ enrolled in @BMTCTN 1703! 😱 Important analysis by @sameem_abedin @MediHumdani @GvHD_Meade and team!! 🙌 https://t.co/afM75mk4nk
#PTCyrules
0
2
7
🚨Breaking News/Good News from #ASH24🚨 >90% 1-year OS in PTCy-treated alloHCT recipients age 70+ enrolled in @BMTCTN 1703! 😱 Important analysis by @sameem_abedin @MediHumdani @GvHD_Meade and team!! 🙌 https://t.co/afM75mk4nk
#PTCyrules
2
8
44
Wonderful sharing the stage with these rising stars! @amjimenezmd @ipolitikos
Excited to chair the “There’s a Donor for Everyone” session at #CBC2024, thanks to @CordBloodAssn. Honored to share the stage with @MGooptu and @ipolitikos. Big strides in HCT access, but there’s still more to do! @nmdp_org @SylvesterCancer
0
1
4
In @JCO_ASCO, @DanaFarber @CIBMTR researchers found that using post-transplant cyclophosphamide results in comparable outcomes between HLA-matched & mismatched unrelated donor hematopoietic cell transplants, expanding access for patients of all ancestries.
ascopubs.org
PURPOSEAccess to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether...
0
4
7
@JCO_ASCO @BrianShafferMD Important paper from @CIBMTR and @nmdp_org demonstrating the evolving potential for PTCy to expand access to HCT for all patients regardless of ancestry
0
1
4
Hahaha! This is what my better half is doing while I twiddle my thumbs in clinic ☺️
The #MicrosoftOutage is the perfect time for teaching chest radiology by one of best, Dr. Mark Hammer! @BWHRadEdu @MassGenBrigham
0
0
5
Wow! This is incredible work that can really open up during our transplantation to many more patients. What a remarkable study!
Remember when we used to avoid mismatched unrelated donor transplants for fear of worse GVHD and NRM outcomes? Those days are over. Congrats to the study team!! 🎉@CIBMTR @nmdp_org @BrianShafferMD @MGooptu @GvHD_Meade @spellman_s @amjimenezmd @DrMonzrAlMalki #PTCyrules
0
1
3
This is extremely important work supported by @nmdp_org and @CIBMTR. Use of MMUD with PTCy truly means there are donors for all! | PTCy–Based GVHD Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors https://t.co/9DyU63KJly
2
16
51